SF tech startup Atomwise gets $45M for AI-powered drug design software
A Silicon Valley software company that’s using artificial intelligence to take the guess work out of structure-based drug design is trotting out a sizable Series A round this morning. The deal includes investors that run the gamut, from tech to biopharma to agrochemicals.
The company is called Atomwise, and it’s hauling in $45 million in a round led by Monsanto Growth Ventures, tech investors DCVC (Data Collective), and B Group Capital – the VC fund founded by Facebook co-founder Eduardo Saverin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.